Literature DB >> 8449573

Helicobacter pylori and gastric cancer.

J Parsonnet1.   

Abstract

Gastric cancer remains among the leading types of cancer worldwide. There is now convincing evidence linking H. pylori to adenocarcinomas of the gastric antrum, body, and fundus. These tumors are rapidly decreasing in incidence in the United States, whereas cardia tumors, tumors unassociated with H. pylori infection, are on the increase. Although criteria for causality have not been completely fulfilled for H. pylori and adenocarcinoma, there are plausible mechanisms by which chronic inflammation could induce carcinogenesis ("mitosis causes mutagenesis"). Because gastric cancer is unusual in the United States, screening and treatment of H. pylori in the general population are unwarranted. Chemoprevention in high-risk populations, however, could potentially be used to decrease risk for adenocarcinomas distal to the cardia.

Entities:  

Mesh:

Year:  1993        PMID: 8449573

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  50 in total

Review 1.  ACP. Best practice no 154. February 1999. Helicobacter pylori.

Authors:  C A McNulty; J I Wyatt
Journal:  J Clin Pathol       Date:  1999-05       Impact factor: 3.411

Review 2.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

3.  H pylori infection and systemic antibodies to CagA and heat shock protein 60 in patients with coronary heart disease.

Authors:  Cristina Lenzi; Alberto Palazzuoli; Nicola Giordano; Giuliano Alegente; Catia Gonnelli; Maria-Stella Campagna; Annalisa Santucci; Michele Sozzi; Panagiotis Papakostas; Fabio Rollo; Ranuccio Nuti; Natale Figura
Journal:  World J Gastroenterol       Date:  2006-12-28       Impact factor: 5.742

4.  Isolation of recombinant protective Helicobacter pylori antigens.

Authors:  D Hocking; E Webb; F Radcliff; L Rothel; S Taylor; G Pinczower; C Kapouleas; H Braley; A Lee; C Doidge
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

5.  Harvard report on cancer prevention. Causes of human cancer. Infectious agents.

Authors: 
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

6.  Structural basis for shikimate-binding specificity of Helicobacter pylori shikimate kinase.

Authors:  Wen-Chi Cheng; Yu-Ning Chang; Wen-Ching Wang
Journal:  J Bacteriol       Date:  2005-12       Impact factor: 3.490

7.  Most Helicobacter pylori-infected patients have specific antibodies, and some also have H. pylori antigens and genomic material in bile: is it a risk factor for gallstone formation?

Authors:  N Figura; F Cetta; M Angelico; G Montalto; D Cetta; L Pacenti; C Vindigni; D Vaira; F Festuccia; A De Santis; G Rattan; R Giannace; S Campagna; C Gennari
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

Review 8.  Sequence-based identification of microbial pathogens: a reconsideration of Koch's postulates.

Authors:  D N Fredricks; D A Relman
Journal:  Clin Microbiol Rev       Date:  1996-01       Impact factor: 26.132

9.  Identification and characterization of a metalloprotease activity from Helicobacter pylori.

Authors:  H J Windle; D Kelleher
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

10.  Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma.

Authors:  T M Hagen; S Huang; J Curnutte; P Fowler; V Martinez; C M Wehr; B N Ames; F V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.